Why the study?
Do novel pharmacological therapies (Zilebesiran, lorundrostat, baxdrostat) lower blood pressure and improve outcomes in patients with hypertension?
Do novel pharmacological therapies (Zilebesiran, lorundrostat, baxdrostat) lower blood pressure and improve outcomes in patients with hypertension?
Novel therapies such as Zilebesiran, lorundrostat, and baxdrostat show significant potential for hypertension management, highlighting future challenges in reimbursement and healthcare implementation once licensed.
May warrant specialist use in resistant hypertension once licensed; leaves open reimbursement and implementation challenges.[[1]](https://www.ovid.com/jnls/co-nephrolhypertens/abstract/10.1097/mnh.
Novel therapies (Zilebesiran, lorundrostat, baxdrostat) have shown great potential in lowering BP that is clinically meaningful to help improve cardiovascular and renal outcomes. ASI therapies lorundrostat and baxdrostat are close to being licensed for HTN. Once commercially available and recommended in treatment guidelines, the next big challenge will be reimbursement and implementation model in different healthcare systems.
No takes yet. Share an insight, caveat, or question.
Saxena et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: